

Table 1 - continued

Clinical signs  
Male, Female

Study No. P030098

Sex	Group and dose	Clinical sign	Days																					
			44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65
Female	Control	Number of examined	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	
		No abnormality	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 mg/kg	Number of examined	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
		No abnormality	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale eyes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20 mg/kg	Number of examined	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
		No abnormality	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Abdominal respiration	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Piloerection	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	Dead	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	100 mg/kg	Number of examined	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
No abnormality		20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	
Corn		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Mass		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Swelling of limbs		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued

Clinical signs  
Male, Female

Study No. P030098

Sex	Group and dose	Clinical sign	Days																					
			66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87
Female	Control	Number of examined	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
		No abnormality	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
		Corn Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 mg/kg	Number of examined	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
		No abnormality	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
		Corn Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale eyes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20 mg/kg	Number of examined	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
		No abnormality	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20
		Corn Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Abdominal respiration	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Piloerection	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dead		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
100 mg/kg	Number of examined	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	
	No abnormality	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	20	
	Corn Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued

Clinical signs  
Male, Female

Study No. P030098

Sex	Group and dose	Clinical sign	Days																					
			88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109
Female	Control	Number of examined	20	20	20	20	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	20	20	20	20	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 mg/kg	Number of examined	20	20	20	20	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	20	20	20	20	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale eyes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20 mg/kg	Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Number of examined	20	20	20	20	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
No abnormality		20	20	20	20	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
Corn		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Mass		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Abdominal respiration		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
100 mg/kg	Piloerection	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Dead	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Number of examined	20	20	20	20	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	No abnormality	20	20	20	20	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued  
Clinical signs  
Male, Female

Sex	Group and dose	Clinical sign	Days																				
			110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale eyes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20 mg/kg	Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
No abnormality		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
Corn		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Mass		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Abdominal respiration		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
100 mg/kg	Piloerection	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Dead	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued

Clinical signs  
Male, Female

Study No. P030098

Sex	Group and dose	Clinical sign	Days																					
			132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale eyes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20 mg/kg	Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Abdominal respiration		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
100 mg/kg	Piloerection	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Dead	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued Clinical signs  
Male, Female

Sex	Group and dose	Clinical sign	Days																					
			154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale eyes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20 mg/kg	Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Abdominal respiration	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Piloerection	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	100 mg/kg	Dead	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
No abnormality		10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
Corn		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued  
Clinical signs  
Male, Female

Sex	Group and dose	Clinical sign	Days																					
			176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Corn		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Mass		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Abdominal respiration		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Piloerection		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Dead	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
100 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued Clinical signs  
Male, Female

Sex	Group and dose	Clinical sign	Days																					
			198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale eyes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20 mg/kg	Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Abdominal respiration		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
100 mg/kg	Piloerection	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Dead	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	



Table 1 - continued

Clinical signs  
Male, Female

Study No. P030098

Sex	Group and dose	Clinical sign	Days																					
			220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale eyes Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Abdominal respiration	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Piloerection Dead		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
100 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued Clinical signs  
Male, Female

Sex	Group and dose	Clinical sign	Days																					
			242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	9	9	9	9	9	9	9
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	9	9	9	9	9	8
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
Corn		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Mass		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Abdominal respiration		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Dead		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
100 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued Clinical signs  
Male, Female

Study No. P030098

Sex	Group and dose	Clinical sign	Days																						
			264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	10	10	10	10	
		Corn	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	
		Corn	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		Mass	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Pale eyes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	20 mg/kg	Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Abdominal respiration		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
100 mg/kg	Piloerection	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Dead	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued

Clinical signs  
Male, Female

Study No. P030098

Sex	Group and dose	Clinical sign	Days																						
			286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10		
		No abnormality	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	
		Corn Mass	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	
		Corn Mass	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	
		Pale skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Pale eyes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	20 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	9	9	9	9	9	
		No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	9	9	9	9	9	9	9	9	9	
		Corn Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Hypoactivity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Abdominal respiration	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0
		Piloerection	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	0	0	0	0	0
Dead		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0		
100 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10		
	No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10		
	Corn Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
			0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued

Clinical signs  
Male, Female

Study No. P030098

Sex	Group and dose	Clinical sign	Days																					
			308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
		No abnormality	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	9	9	9	9	9	9	9
		Corn Mass	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	0	0	0	0	0	0	0
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8
		Corn	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		Mass	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		Pale skin	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1
		Pale eyes Hypoactivity	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	1	1	1	1	1	1	1
	20 mg/kg	Number of examined	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
		No abnormality	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	8	8	8	8
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1
Mass		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Abdominal respiration		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Piloerection Dead		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
100 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Table 1 - continued Clinical signs  
Male, Female

Sex	Group and dose	Clinical sign	Days																					
			330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	8	8	8	8	8	8
		Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1
		Mass	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	7	7
		Corn	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	2	2
		Mass	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		Pale skin	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		Pale eyes	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		Hypoactivity	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	20 mg/kg	Number of examined	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9	9
		No abnormality	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8	8
		Corn	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
		Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hypoactivity		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Abdominal respiration		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Piloerection		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Dead		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
100 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	
	No abnormality	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10	9	
	Corn	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	Mass	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
	Swelling of limbs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

98 37

Table 1 - continued Clinical signs  
Male, Female

Study No. P030098

Sex	Group and dose	Clinical sign	Days												
			352	353	354	355	356	357	358	359	360	361	362	363	364
Female	Control	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	8	8	8	8	8	8	8	8	8	8	7	7	7
		Corn Mass	1	1	1	1	1	1	1	1	1	1	2	2	2
	4 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10
		No abnormality	7	7	7	7	7	7	7	7	7	7	7	7	7
		Corn Mass	2	2	2	2	2	2	2	2	2	2	2	2	2
		Pale skin	1	1	1	1	1	1	1	1	1	1	1	1	1
		Pale eyes	1	1	1	1	1	1	1	1	1	1	1	1	1
		Hypoactivity	1	1	1	1	1	1	1	1	1	1	1	1	1
	20 mg/kg	Number of examined	9	9	9	9	9	9	9	9	9	9	9	9	9
		No abnormality	8	8	8	8	8	8	8	8	8	8	7	7	7
		Corn Mass	1	1	1	1	1	1	1	1	1	1	1	1	1
		Hypoactivity	0	0	0	0	0	0	0	0	0	0	1	1	1
		Abdominal respiration	0	0	0	0	0	0	0	0	0	0	0	0	0
		Piloerection	0	0	0	0	0	0	0	0	0	0	0	0	0
Dead		0	0	0	0	0	0	0	0	0	0	0	0	0	
100 mg/kg	Number of examined	10	10	10	10	10	10	10	10	10	10	10	10	10	
	No abnormality	8	8	8	8	8	6	6	6	6	6	6	6	6	
	Corn Mass	1	1	1	1	1	3	3	3	3	3	3	3	3	
	Swelling of limbs	1	1	1	1	1	1	1	1	1	1	1	1	1	
		0	0	0	0	0	1	1	1	1	1	1	1	1	

Table 2 Body weights  
Male, Female

Sex	Group and dose		Body weight (g) on day												
			1	8	15	22	29	36	43	50	57	64	71	78	85
Male	Control	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	212.9	276.8	333.8	378.3	426.4	465.9	495.0	526.4	548.1	566.7	585.6	601.7	615.6
		S.D.	±8.9	±14.2	±18.2	±22.3	±26.5	±29.5	±33.2	±39.4	±40.7	±42.5	±46.8	±49.7	±49.9
	4 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	211.7	273.4	325.9	367.7	412.5	449.1	475.6	504.5	524.0	542.1	559.0	574.5	590.4
		S.D.	±9.0	±14.9	±21.7	±27.1	±33.4	±40.2	±47.6	±53.3	±55.1	±57.9	±59.8	±61.3	±63.6
	20 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	211.2	277.0	333.4	376.8	421.3	458.5	487.3	514.8	537.1	557.7	576.2	596.2	610.6
		S.D.	±9.7	±17.4	±25.2	±29.8	±34.6	±40.0	±44.4	±47.7	±49.3	±52.9	±56.2	±59.9	±62.0
	100 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	210.4	281.7	342.1	389.9	439.0	478.1	506.9	536.8	560.2	580.3	601.8	620.5	630.5
		S.D.	±8.8	±15.4	±23.0	±28.7	±32.5	±36.9	±38.8	±43.4	±44.4	±46.8	±50.3	±52.6	±56.0
Female	Control	N	20	20	20	20	20	20	20	20	20	20	20	20	
		Mean	157.2	186.0	215.5	233.2	252.7	263.2	277.1	286.1	294.5	304.1	309.2	316.3	321.0
		S.D.	±5.9	±8.8	±11.4	±13.7	±17.1	±17.3	±18.5	±20.5	±23.4	±23.2	±25.8	±26.3	±28.9
	4 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	157.3	186.3	215.4	233.8	250.0	263.3	274.2	283.4	290.7	300.3	305.4	311.1	315.8
		S.D.	±7.4	±10.5	±12.4	±12.3	±14.4	±15.4	±15.8	±14.8	±17.2	±17.3	±19.4	±19.6	±20.4
	20 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	156.7	186.7	217.4	233.2	251.7	264.7	274.9	284.5	291.8	301.4	309.3	315.5	319.5
		S.D.	±7.6	±9.8	±13.9	±14.9	±15.7	±15.9	±19.7	±20.0	±21.8	±22.7	±25.2	±25.0	±26.0
	100 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	156.8	189.1	218.6	237.0	254.3	266.4	279.6	289.2	296.8	303.9	309.9	317.3	321.3
		S.D.	±8.6	±10.9	±17.0	±17.6	±22.3	±21.3	±23.9	±25.4	±27.0	±27.1	±27.8	±29.7	±32.6

Not significantly different from control.



Table 2 - continued

Body weights  
Male, Female

Study No. P030098

Sex	Group and dose	Body weight (g) on day												
		91	92	120	148	176	204	232	260	288	316	344	364	
Male	Control	N	20	10	10	10	10	10	10	10	10	10	10	10
		Mean	624.3	615.4	659.2	692.9	729.8	752.6	779.8	814.6	839.3	849.8	866.0	876.1
		S.D.	±49.1	±51.1	±59.5	±65.2	±71.2	±73.5	±77.0	±88.4	±94.7	±101.8	±103.8	±107.7
	4 mg/kg	N	19	10	9	9	9	9	9	9	9	9	8	8
		Mean	602.2	594.0	635.7	671.9	705.7	727.1	752.1	781.1	796.5	812.3	813.4	823.7
		S.D.	±66.3	±69.1	±70.0	±71.2	±80.3	±78.6	±79.7	±85.4	±88.5	±97.0	±81.8	±82.1
	20 mg/kg	N	20	10	10	10	10	9	9	8	8	8	8	8
		Mean	621.8	625.6	669.9	706.5	737.9	778.1	800.4	802.1	823.7	836.4	856.0	866.8
		S.D.	±65.7	±84.0	±96.1	±105.5	±110.8	±119.2	±126.9	±133.2	±135.2	±139.0	±140.4	±140.4
	100 mg/kg	N	19	10	10	10	10	10	10	10	10	10	10	10
		Mean	643.5	635.1	680.7	716.2	750.1	786.7	816.0	844.0	866.0	880.2	901.2	907.3
		S.D.	±57.7	±72.6	±81.9	±86.8	±96.7	±107.9	±118.8	±130.9	±135.4	±139.1	±139.8	±136.5
Female	Control	N	20	10	10	10	10	10	10	10	10	10	10	
		Mean	323.7	314.2	326.3	338.8	353.8	367.5	385.0	399.1	414.8	428.6	441.0	449.6
		S.D.	±28.2	±30.5	±32.2	±33.4	±40.8	±49.4	±53.2	±56.2	±59.6	±69.4	±70.9	±78.0
	4 mg/kg	N	20	10	10	10	10	10	10	10	10	10	10	10
		Mean	320.1	315.0	329.0	340.5	352.9	368.6	385.1	391.3	408.5	414.4	423.4	426.0
		S.D.	±20.5	±20.9	±21.5	±24.8	±25.9	±27.2	±28.4	±36.6	±42.9	±45.4	±48.4	±54.3
	20 mg/kg	N	20	10	10	10	10	10	10	10	10	9	9	9
		Mean	323.9	314.0	325.5	340.6	357.2	372.2	388.2	401.4	418.5	425.6	445.0	454.1
		S.D.	±27.7	±11.4	±9.2	±15.6	±17.1	±19.1	±23.2	±23.7	±26.5	±32.9	±33.7	±39.4
	100 mg/kg	N	20	10	10	10	10	10	10	10	10	10	10	10
		Mean	326.8	329.1	346.0	358.2	374.6	388.2	408.5	421.7	439.3	453.5	467.4	471.0
		S.D.	±30.6	±34.7	±39.5	±48.0	±51.3	±56.3	±67.1	±69.0	±78.1	±84.0	±96.4	±94.1

Not significantly different from control.

Table 3 Food consumption  
Male, Female

Sex	Group and dose		Food consumption (g) on day												
			2	8	15	22	29	36	43	50	57	64	71	78	85
Male	Control	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	23.3	25.1	25.2	25.6	26.0	25.5	24.2	25.1	23.4	23.5	22.9	22.9	21.9
		S.D.	±1.6	±2.0	±2.7	±2.2	±2.5	±2.6	±2.0	±3.1	±2.4	±2.7	±3.1	±3.0	±2.4
	4 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	23.0	23.9	24.6	25.0	24.5	25.0	23.3	24.0	23.2	22.9	21.9	21.8	22.8
		S.D.	±1.6	±2.3	±3.1	±2.8	±3.8	±2.9	±2.8	±3.4	±3.1	±2.8	±3.2	±3.0	±4.0
	20 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	24.1	25.1	25.5	26.2	25.4	25.7	25.0	25.7	24.7	24.6	24.0	23.5	23.5
		S.D.	±2.6	±2.8	±3.0	±3.2	±3.4	±3.0	±3.3	±2.8	±3.1	±3.0	±3.4	±3.3	±3.2
	100 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	24.1	24.6	26.5	26.8	26.3	25.9	25.2	25.8	26.1*	24.5	24.7	24.6	23.8*
		S.D.	±1.7	±2.6	±2.8	±4.0	±3.4	±3.3	±2.4	±2.6	±3.2	±3.3	±3.9	±3.4	±6.2
Female	Control	N	20	20	20	20	20	20	20	20	20	20	20	20	
		Mean	16.0	15.4	16.4	16.4	17.2	15.6	17.5	16.0	16.5	15.7	15.2	16.5	14.5
		S.D.	±1.7	±1.9	±2.3	±2.3	±2.1	±2.1	±2.1	±2.0	±2.7	±2.2	±2.2	±2.3	±2.3
	4 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	16.2	16.0	16.4	16.4	16.6	16.4	16.7	15.3	15.9	15.8	16.3	14.9	15.1
		S.D.	±1.5	±1.9	±2.3	±1.7	±3.0	±2.4	±3.0	±2.4	±2.7	±1.6	±2.3	±2.7	±2.5
	20 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	16.2	15.2	16.6	16.2	16.9	16.7	16.5	16.9	16.4	15.9	16.4	16.7	15.6
		S.D.	±2.2	±1.9	±2.3	±2.7	±3.0	±2.5	±2.5	±2.8	±3.0	±2.7	±2.8	±3.1	±3.1
	100 mg/kg	N	20	20	20	20	20	20	20	20	20	20	20	20	20
		Mean	16.5	15.7	16.9	16.9	18.3	16.6	17.2	17.1	17.5	15.5	16.1	17.3	15.7
		S.D.	±1.2	±1.3	±2.5	±2.7	±3.7	±2.7	±2.7	±2.4	±2.6	±2.4	±3.2	±2.9	±2.9

\*: P&lt;0.05 (significantly different from control).

Table 3 - continued Food consumption  
Male, Female

Sex	Group and dose	Food consumption(g) on day												
		91	92	120	148	176	204	232	260	288	316	344	364	
Male	Control	N	20	10	10	10	10	10	10	10	10	10	10	10
		Mean	22.8	21.7	22.0	21.4	20.3	18.6	18.8	20.1	16.9	17.6	18.6	17.3
		S.D.	±2.0	±1.4	±2.5	±1.8	±2.7	±2.2	±2.4	±2.4	±2.2	±1.6	±2.9	±1.9
	4 mg/kg	N	19	10	9	9	9	9	9	9	9	9	8	8
		Mean	22.3	21.6	21.3	21.3	20.4	19.0	18.7	19.4	17.6	18.1	17.8	16.6
		S.D.	±3.3	±4.4	±3.6	±3.3	±4.2	±2.3	±3.0	±4.4	±3.9	±2.7	±1.6	±2.5
	20 mg/kg	N	20	10	10	10	10	9	9	8	8	8	8	8
		Mean	24.1	23.1	23.5	22.2	21.2	19.9	18.7	19.1	17.0	18.7	18.5	17.2
		S.D.	±3.7	±3.5	±3.3	±3.0	±2.4	±3.4	±3.9	±4.3	±4.0	±2.5	±2.8	±3.5
	100 mg/kg	N	19	10	10	10	10	10	10	10	10	10	10	10
		Mean	24.9	21.8	23.4	23.1	22.1	20.5	19.5	19.6	19.9	19.9	19.1	17.3
		S.D.	±3.4	±3.3	±3.2	±3.3	±2.6	±4.1	±3.7	±3.6	±2.8	±3.5	±1.9	±1.9
Female	Control	N	20	10	10	10	10	10	10	10	10	10	10	10
		Mean	15.8	14.9	14.7	15.5	15.5	13.7	13.7	14.3	15.4	16.1	12.9	13.0
		S.D.	±2.7	±1.2	±2.2	±1.6	±1.9	±2.8	±0.9	±1.5	±1.7	±2.6	±2.6	±2.6
	4 mg/kg	N	20	10	10	10	10	10	10	10	10	10	10	10
		Mean	16.8	15.7	16.4	15.5	15.9	15.0	14.0	13.0	15.5	15.4	13.8	13.3
		S.D.	±2.5	±3.5	±2.4	±2.3	±2.6	±2.4	±2.5	±2.7	±2.0	±1.3	±1.7	±4.1
	20 mg/kg	N	20	10	10	10	10	10	10	10	10	9	9	9
		Mean	16.5	14.5	15.1	16.3	16.6	15.0	13.8	14.3	15.6	15.9	14.2	15.3
		S.D.	±2.8	±1.5	±1.9	±2.8	±2.4	±2.9	±3.2	±2.7	±2.5	±3.4	±2.6	±3.0
	100 mg/kg	N	20	10	10	10	10	10	10	10	10	10	10	10
		Mean	17.3	15.9	15.8	17.0	18.0	15.6	15.4	14.3	16.4	15.4	15.0	15.1
		S.D.	±2.5	±1.7	±2.7	±2.4	±2.4	±2.5	±2.7	±2.7	±2.3	±3.8	±3.4	±2.6

Not significantly different from control.

Table 4 Urinary findings  
Male, Female, 13w

Sex	Group and dose		Urine volume (mL/24hr)	Osmotic pressure (Osm/kg)	Specific gravity	Na (mEq/24hr)	K (mEq/24hr)	Cl (mEq/24hr)
Male	Control	N	10	10	10	10	10	10
		Mean	13.4	1.512	1.048	0.944	2.187	1.256
		S. D.	±5.1	±0.439	±0.015	±0.273	±0.502	±0.401
	4 mg/kg	N	9	9	9	9	9	9
		Mean	17.6	1.452	1.048	0.852	2.145	1.250
		S. D.	±14.1	±0.596	±0.023	±0.416	±0.777	±0.595
	20 mg/kg	N	10	10	10	10	10	10
		Mean	15.4	1.506	1.047	0.988	2.433	1.422
		S. D.	±7.5	±0.433	±0.015	±0.297	±0.387	±0.387
	100 mg/kg	N	9	9	9	9	9	9
		Mean	14.5	1.454	1.047	1.027	2.449	1.488
		S. D.	±4.7	±0.294	±0.009	±0.456	±0.440	±0.357
Female	Control	N	10	10	10	10	10	10
		Mean	12.5	1.200	1.039	0.755	1.679	1.101
		S. D.	±7.6	±0.479	±0.017	±0.359	±0.490	±0.490
	4 mg/kg	N	10	10	10	10	10	10
		Mean	12.8	1.206	1.040	0.919	1.846	1.267
		S. D.	±7.1	±0.410	±0.014	±0.240	±0.507	±0.318
	20 mg/kg	N	10	10	10	10	10	10
		Mean	8.8	1.617	1.054	0.774	1.908	1.204
		S. D.	±3.3	±0.385	±0.013	±0.300	±0.463	±0.315
	100 mg/kg	N	10	10	10	10	10	10
		Mean	12.3	1.169	1.039	0.883	1.807	1.231
		S. D.	±5.3	±0.400	±0.014	±0.232	±0.368	±0.196

Not significantly different from control.

One male in the 4 mg/kg group was imminently sacrificed when moribund and one male in the 100 mg/kg group died.

Table 4 - continued  
Urinary findings  
Male, Female, 13w

Sex	Group and dose	Number of animals	Color		pH						Protein			Glucose	Ketone body
			PY	Y	5.5	6.0	6.5	7.0	8.0	8.5	-	±	+	-	-
Male	Control	10	0	10	0	0	0	1	8	1	5	3	2	10	10
	4 mg/kg	9	1	8	0	0	0	1	6	2	2	4	3	9	9
	20 mg/kg	10	1	9	0	0	0	0	8	2	4	4	2	10	10
	100 mg/kg	9	0	9	0	0	0	2	5	2	0	5	4	9	9
Female	Control	10	1	9	0	2	0	4	3	1	8	2	0	10	10
	4 mg/kg	10	1	9	1	0	0	0	7	2	10	0	0	10	10
	20 mg/kg	10	0	10	0	0	1	0	8	1	9	1	0	10	10
	100 mg/kg	10	0	10	0	3	0	1	4	2	10	0	0	10	10

Not significantly different from control.

Abbreviation: PY, pale yellow; Y, yellow; YB, yellowish brown; B, brown.

Grade sign: -, none; ±, trace; +, slight; ++, moderate; +++, severe; +++++, very severe.

One male in the 4 mg/kg group was imminently sacrificed when moribund and one male in the 100 mg/kg group died.

Table 4 - continued  
Urinary findings  
Male, Female, 13w

Sex	Group and dose	Number of animals	Bilirubin	Occult blood	Urobilinogen (mg/dL)
			-	-	<1
Male	Control	10	10	10	10
	4 mg/kg	9	9	9	9
	20 mg/kg	10	10	10	10
	100 mg/kg	9	9	9	9
Female	Control	10	10	10	10
	4 mg/kg	10	10	10	10
	20 mg/kg	10	10	10	10
	100 mg/kg	10	10	10	10

Not significantly different from control.

Grade sign: -, none; ±, trace; +, slight; ++, moderate; +++, severe; +++++, very severe.

One male in the 4 mg/kg group was imminently sacrificed when moribund and one male in the 100 mg/kg group died.

Table 4 - continued

Urinary findings  
Male, Female, 13w

Study No. P030098

Sex	Group and dose	Number of animals	Urinary sediment						
			Epithelial cells	Erythrocytes	Leukocytes	Casts	Crystals		
			-	-	-	-	-	+	++
Male	Control	10	10	10	10	10	9	1	0
	4 mg/kg	9	9	9	9	9	7	2	0
	20 mg/kg	10	10	10	10	10	8	2	0
	100 mg/kg	9	9	9	9	9	8	0	1
Female	Control	10	10	10	10	10	10	0	0
	4 mg/kg	10	10	10	10	10	10	0	0
	20 mg/kg	10	10	10	10	10	10	0	0
	100 mg/kg	10	10	10	10	10	10	0	0

Not significantly different from control.

Grade signs are as follows.

Epithelial cells: -, < 3/field; +, 3/field  $\leq$  and < 10/field; ++, 10/field  $\leq$  and < 20/field; +++,  $\geq$  20/field.Erythrocytes: -, < 10/field; +, 10/field  $\leq$  and < 30/field; ++, 30/field  $\leq$  and < 100/field; +++, countless.Leukocytes: -, < 3/field; +, 3/field  $\leq$  and < 20/field; ++, 20/field  $\leq$  and < 40/field; +++,  $\geq$  40/field.Casts: -, none; +,  $\leq$  1/all field.Crystals: -, < 10/field; +, 10/field  $\leq$  and < 20/field; ++, 20/field  $\leq$  and < 30/field; +++, countless.

One male in the 4 mg/kg group was imminently sacrificed when moribund and one male in the 100 mg/kg group died.

Table 5 Urinary findings  
Male, Female, 52w

Study No. P030098

Sex	Group and dose		Urine volume	Osmotic pressure	Specific gravity	Na	K	Cl
			(mL/24hr)	(Osm/kg)		(mEq/24hr)	(mEq/24hr)	(mEq/24hr)
Male	Control	N	10	10	10	10	10	10
		Mean	8.7	1.714	1.058	0.506	1.594	0.684
		S.D.	±3.4	±0.415	±0.019	±0.203	±0.380	±0.309
	4 mg/kg	N	8	8	8	8	8	8
		Mean	10.4	1.435	1.050	0.501	1.395	0.652
		S.D.	±5.7	±0.527	±0.019	±0.183	±0.232	±0.285
	20 mg/kg	N	8	8	8	8	8	8
		Mean	11.3	1.388	1.048	0.611	1.583	0.834
		S.D.	±5.9	±0.446	±0.017	±0.457	±0.560	±0.569
	100 mg/kg	N	10	10	10	10	10	10
		Mean	13.0	1.275	1.044	0.701	1.648	0.832
		S.D.	±4.8	±0.259	±0.011	±0.356	±0.246	±0.365
Female	Control	N	10	10	10	10	10	10
		Mean	14.2	0.992	1.034	0.844	1.831	1.134
		S.D.	±5.7	±0.280	±0.010	±0.254	±0.377	±0.301
	4 mg/kg	N	10	10	10	10	10	10
		Mean	15.1	1.046	1.037	0.891	1.930	1.193
		S.D.	±7.3	±0.469	±0.019	±0.281	±0.372	±0.388
	20 mg/kg	N	9	9	9	9	9	9
		Mean	18.0	0.810	1.028	0.879	1.971	1.229
		S.D.	±5.7	±0.256	±0.009	±0.278	±0.410	±0.369
	100 mg/kg	N	10	10	10	10	10	10
		Mean	13.8	1.158	1.042	0.834	1.927	1.152
		S.D.	±7.1	±0.417	±0.017	±0.244	±0.416	±0.315

Not significantly different from control.

One male in the 4 mg/kg group died and one male in the 4 mg/kg group was imminently sacrificed when moribund.

Two males and one female in the 20 mg/kg group died.



Table 5 - continued

Urinary findings  
Male, Female, 52w

Study No. P030098

Sex	Group and dose	Number of animals	Color		pH								Protein					Glucose
			PY	Y	5.0	5.5	6.0	6.5	7.0	7.5	8.0	8.5	-	±	+	++	+++	-
Male	Control	10	0	10	0	0	0	0	0	2	7	1	0	1	6	2	1	10
	4 mg/kg	8	0	8	0	0	0	0	0	3	4	1	0	1	5	1	1	8
	20 mg/kg	8	0	8	0	0	0	1	2	3	2	0*	0	0	3	4	1	8
	100 mg/kg	10	0	10	0	0	0	0	5	1	4	0	0	2	1	5	2	10
Female	Control	10	0	10	1	1	0	1	3	0	4	0	4	3	1	2	0	10
	4 mg/kg	10	2	8	0	2	0	1	3	1	3	0	2	4	2	2	0	10
	20 mg/kg	9	2	7	2	1	2	2	2	0	0	0	2	1	2	4	0	9
	100 mg/kg	10	2	8	0	2	0	0	4	0	4	0	2	1	3	1	3	10

\*: P&lt;0.05 (significantly different from control).

Abbreviation: PY, pale yellow; Y, yellow; YB, yellowish brown; B, brown.

Grade sign: -, none; ±, trace; +, slight; ++, moderate; +++, severe; +++++, very severe.

One male in the 4 mg/kg group died and one male in the 4 mg/kg group was imminently sacrificed when moribund.

Two males and one female in the 20 mg/kg group died.